Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study
December 03, 2021 02:00 ET | Immunicum AB
Press Release  Stockholm, Sweden, December 3, 2021 Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study Immunicum AB (“Immunicum”, publ; IMMU.ST), a biopharmaceutical...
Immunicum tillkännager avslutad Fas Ib och tidig stängning av ILIAD-studien
December 03, 2021 02:00 ET | Immunicum AB
Pressmeddelande 3 december 2021 Immunicum tillkännager avslutad Fas Ib och tidig stängning av ILIAD-studienImmunicum AB (“Immunicum”, publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på...
Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study
July 26, 2021 02:00 ET | Immunicum AB
Press Release 26 July 2021 Immunicum Announces Positive Review by Data Safety Monitoring Board for Phase Ib Part of ILIAD Study  -- Independent Data Safety and Monitoring Board (DSMB) issues...
Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien
July 26, 2021 02:00 ET | Immunicum AB
Press Release 26 July 2021  Immunicum tillkännager positiv granskning från Data Safety Monitoring Board av fas Ib IILIAD-studien -- Independent Data Safety and Monitoring Board (DSMB) har avgivit...